Wart injections: vitamin D3 versus acyclovir

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

People with common, plantar, flat, or periungual warts will be assigned to receive intralesional injections of either acyclovir or vitamin D3, with 20 participants in each group. Injections are given every two weeks for up to four sessions, with photographs and measurements of wart size and number taken at each visit. The primary outcome is complete clearance of warts by week 8, and participants are followed for up to three months to monitor recurrence and side effects. Safety and local adverse reactions will be recorded and compared between the two groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 12 years and above with clinically diagnosed cutaneous warts
* Common, plantar, flat, or periungual warts
* Both treatment-naïve patients and those with recalcitrant warts

Exclusion Criteria:

* Pregnant or lactating women
* Immunocompromised patients
* Individuals with history of hypersensitivity to vitamin D3 or acyclovir
* Individuals receiving systemic immunosuppressive or antiviral therapy
* Patients with secondary infection at injection site
* Patients who had received any topical or destructive treatment for wart in previous three months

Where it's running

• Railway General Hospital, Railway Carriage Factory Rd, Railway Scheme 7, Rawalpindi
  Rawalpindi, Punjab Province, Pakistan Recruiting
• Riphah International Hospital, Islamabad Expy, Sector A DHA Phase 5, Islamabad
  Islamabad, Pakistan Recruiting

Study contacts

• Principal investigator: Fatima Sajid, FCPS — Riphah International University
• Study coordinator: Fatima Sajid, FCPS
• Email: fatima.sajid@riphah.edu.pk
• Phone: +92 334 435 2228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating the effectiveness of 2LVERU® for treating warts

  This study is testing if a new treatment called 2LVERU® can help people aged 3 and older get rid of different types of warts better than a placebo.

  Recruiting at 5 sites Phase 4 Labo'Life · Bouge and 5 other locations · NCT03977753

• Cantharidin and occlusion in verruca epithelium: testing a topical treatment for common warts

  This Phase 3 study tests VP-102/TO-208 (cantharidin) vs. a vehicle to see if it clears common warts in people 2 years and older who have a normal immune system.

  Recruiting at 14 sites Phase 3 Verrica Pharmaceuticals Inc. · San Diego, California and 19 other locations · NCT07637734

• Long-term follow-up of cantharidin (YCANTH/VP-102/TO-208) treatment for common warts

  This follow-up will try applying cantharidin (YCANTH/VP-102/TO-208) every ~21 days for up to four applications to see if it safely clears remaining common warts in people who completed earlier COVE studies.

  Recruiting at 12 sites Phase 3 Verrica Pharmaceuticals Inc. · Saint Augustine, Florida and 11 other locations · NCT07457918

• Tirbanibulin ointment for treating warts in children

  This study is testing if a new ointment can help treat hand warts in kids aged 8 to 18 more effectively and comfortably than current treatments.

  Recruiting Phase 4 The Skin Center Dermatology Group · New City, New York · NCT06791525

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.